INBX Stock: Price, Earnings History and SEC Filings
Inhibrx Biosciences, Inc. (INBX) last traded at $71.78, down 2.54% on the latest session and down 28.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-2.34 against an analyst estimate of $-2.50, a beat of 6.4%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
INBX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 13, 2026 | $-2.34 | $-2.50 | +6.40% |
| Mar 2026 | May 14, 2026 | $-2.15 | $-2.37 | +9.28% |
INBX beat the analyst EPS estimate in 2 of its last 2 reported quarters. Source: Nasdaq.
How INBX reacts to earnings
Across its last 8 earnings releases, INBX moved 5.5% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-13 | After close | -8.91% |
| 2026-05-14 | After close | -6.47% |
| 2026-03-19 | After close | -6.09% |
| 2025-11-13 | After close | +6.04% |
| 2025-08-13 | After close | +1.57% |
| 2025-05-14 | After close | +10.89% |
| 2025-03-17 | After close | +0.43% |
| 2024-11-14 | After close | -3.49% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
INBX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $1M | -$140M | -$130M | -10773.5% | $-9.04 |
| 2024 | $200000 | $1.7B | -$197M | 843786.0% | $112.62 |
| 2023 | $2M | -$241M | -$198M | -13408.9% | $-20.48 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for INBX
- 8-K · Sep 28, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Sep 8, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Aug 13, 2026Results of operations, Financial statements and exhibits
- 10-Q · Aug 13, 2026
- 8-K · Jul 16, 2026Material agreement, New financial obligation, Unregistered share sale
- 8-K · Jun 15, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Jun 3, 2026Shareholder vote
- 8-K · May 14, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 14, 2026
- 8-K · May 11, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
Insider filing activity
INBX insiders filed 9 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
INBX news
- Inhibrx Biosciences (INBX) Stock Looks Hard To Pin Down At This PriceOct 23, 2026 · finance.yahoo.com
- Insiders Load Up on These 2 ‘Strong Buy’ Stocks — Should You Follow Their Footsteps?Oct 21, 2026 · finance.yahoo.com
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. (INBX) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.